Spotlight on Science: Genetics and Side Effects – Dr. Bryan Schneider
One of the most promising new trends in cancer science is the search for personalized medicines – finding treatments that are right for individual patients and identifying those that might not work based on a patient’s genetic makeup and medical history.
In 2009, Komen provided $6 million in research funding to an Indiana University team looking for genetic markers that could predict which patients would respond to a new experimental drug. Soon, the research from this Komen Promise Grant opened promising new doors about genetics and treatment side effects. The team was led by Indiana University’s Bryan Schneider, M.D. (one of our Komen Scholars) and the late David Flockhart, M.D., Ph.D., along with patient advocate Mary Lou Smith, Esq., co-founder of Research Advocacy Network.